Dare Bioscience Inc (DARE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.72+1.11%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DARE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance commercial launch and national dispensing of DARE to PLAY Sildenafil Cream, with initial product revenue expected in Q3 2026.
Stated as a priority in 2 of last 2 quarters. Management expects to begin recording product revenue from DARE to PLAY Sildenafil Cream in Q3 2026. As of 2026-Q2, revenue was $0.2 million, primarily from R&D services, with no product revenue yet. The trajectory matches management's stated timeline with initial revenue anticipated imminently.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“DARE to PLAY Sildenafil Cream progressing toward national dispensing and initial revenue in the third quarter of 2026, with prescriptions and preorders already being accepted.”
“Daré expects to begin recording product revenue from DARE to PLAY this summer, in the third quarter of 2026.”
Commercially launch Flora Sync LF5 vaginal probiotic product with revenue expected to begin in June 2026.
Stated as a priority in 2 of last 2 quarters. Flora Sync LF5 launched commercially in July 2026, marking the first direct product revenue for the company. Prior quarters had no product revenue. The trajectory shows delivery of initial revenue consistent with management's June/July 2026 guidance.
“Launched Flora Sync LF5, the company’s first directly commercialized product, began generating revenue in July.”
“Flora Sync LF5 consumer health product revenue is expected to begin in June 2026.”
Progress Ovaprene Phase 3 trial and initiate DARE-HPV Phase 2 study with funding support and regulatory milestones.
Stated as a priority in 2 of last 2 quarters. Management reported positive interim results for Ovaprene Phase 3 and initiated the DARE-HPV Phase 2 study with expected enrollment of ~100 women. These clinical milestones are on track with planned timelines, indicating delivery consistent with stated goals.
“Positive interim Phase 3 Ovaprene results and initiation of DARE-HPV Phase 2 study expected to enroll ~100 women.”
“Second positive DSMB review of interim data from Ovaprene Phase 3 clinical trial announced; DARE-HPV advancing into Phase 2 clinical study in May 2026.”
Raise capital through Regulation A offerings to support operations and development programs.
Stated as a priority in 4 of last 4 quarters. Management completed multiple closings of Regulation A equity offerings totaling up to 4,854,000 units during this period. These capital raises have supported ongoing operations and development, indicating consistent execution on capital allocation plans.
“Completed closings of previously announced Regulation A offering of up to 4,854,000 units.”
“Completed multiple closings of Regulation A offering of up to 4,854,000 units.”
“Completed closings of Regulation A offering of up to 4,854,000 units.”
“Completed closings of Regulation A offering of up to 4,854,000 units.”
Begin recording product revenue from DARE to PLAY starting in Q2/Q3 2026 as dispensing and sales commence.
Over the trailing year it converted 1.35x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
19 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.